Ligand Pharmaceuticals, Inc. Financial Ratios
LGND / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
12.2%
ROE ranks in the bottom 25% among Health Care companies
Profit Margin
46.4%
Net Income / Revenue
Asset Turnover
0.17
Revenue / Total Assets
Equity Multiplier
1.53
Total Assets / Equity
Composite: 12.2% (reported: 12.2%)
Profitability
Liquidity
Current Ratio
22.23
Quick Ratio
21.98
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.17
Inventory Turnover
-
Days Sales Outstanding
81 days
As of FY2025 · SEC 10-K · Updated Feb 28, 2026
Earnings Quality
Accrual Ratio
+6.0%
+16.7pp YoY
Earnings include a notable portion of accrual components.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.